Stockscreener 앱 받기
3.79
2.32%
-0.09
시간 외 거래:
3.86
0.07
+1.85%
전일 마감가:
$3.88
열려 있는:
$3.92
하루 거래량:
1.65M
Relative Volume:
0.45
시가총액:
$1.01B
수익:
-
순이익/손실:
$-252.18M
주가수익비율:
-3.5755
EPS:
-1.06
순현금흐름:
$-185.29M
1주 성능:
+6.76%
1개월 성능:
-17.25%
6개월 성능:
+21.86%
1년 성능:
+33.45%
1일 변동 폭
$3.72
$3.94
1주일 범위
$3.685
$4.095
52주 변동 폭
$1.26
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.79 | 1.03B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions - Quantisnow
Day Trade: What is the Moat Score of Sana Biotechnology IncJuly 2025 Drop Watch & Fast Entry Momentum Alerts - baoquankhu1.vn
Commit To Purchase Sana Biotechnology At $2.50, Earn 26% Using Options - Nasdaq
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Sana Biotechnology, Inc. (SANA) Stock Analysis: 89% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know - Yahoo Finance
Aug Levels: What are Sana Biotechnology Incs earnings expectationsEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Is Sana Biotechnology Inc. a stock for growth or value investorsJuly 2025 Fed Impact & AI Forecast for Swing Trade Picks - mfd.ru
Sana Biotechnology, Inc. $SANA Position Boosted by Baillie Gifford & Co. - MarketBeat
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet - Finviz
Fundamentals Check: Will Sana Biotechnology Inc benefit from sector rotationEarnings Performance Report & Smart Swing Trading Techniques - baoquankhu1.vn
Sell Signal: Is Sana Biotechnology Inc a stock for growth or value investorsJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips (NASDAQ:SANA) - Seeking Alpha
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Bank of America Securities Reaffirms Their Buy Rating on Sana Biotechnology (SANA) - The Globe and Mail
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Potential 86.60% Upside in the Biotech Arena - DirectorsTalk Interviews
Institution Moves: What is the Moat Score of Sana Biotechnology IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Sana Biotechnology (SANA) Valuation Check After J.P. Morgan Conference Cell Therapy Updates - Sahm
Portfolio Shifts: Will Sana Biotechnology Inc stock hit new highs in YEAR2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
SANA: Gene-edited cell therapy for type 1 diabetes shows durable immune evasion; phase I trials planned - TradingView
Sana Biotechnology, Inc. Updates on Key Programs at J.P. Morgan Conference - TradingView
Sell Signal: Will Sana Biotechnology Inc stock hit new highs in YEARPortfolio Gains Report & Risk Controlled Stock Alerts - baoquankhu1.vn
Gains Report: Why Sana Biotechnology Inc stock attracts high net worth investorsWeekly Stock Summary & Long-Term Capital Growth Ideas - Bộ Nội Vụ
Sana Biotechnology to Present at June 2025 Investor Conferences - FinancialContent
Geopolitics Watch: Why Sana Biotechnology Inc stock attracts high net worth investorsEarnings Growth Summary & Weekly Stock Performance Updates - Bộ Nội Vụ
New Highs: How Sana Biotechnology Inc stock performs in stagflationJuly 2025 Macro Moves & Trade Opportunity Analysis - Bộ Nội Vụ
How rising interest rates impact Sana Biotechnology Inc. stockWalking Comfort Picks & compare fit, width, and feel - Улправда
Sana Biotechnology (SANA) Is Up 11.1% After BofA Endorsement And JPM Update Signal Boost - Sahm
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - Sahm
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Can Sana Biotechnology Inc. stock sustain market leadershipMarket Rally & Stepwise Trade Signal Implementation - ulpravda.ru
Citizens Maintains Sana Biotechnology (SANA) Market Outperform Recommendation - MSN
Is Sana Biotechnology Inc. stock cheap compared to fundamentals2025 Pullback Review & Community Trade Idea Sharing Platform - ulpravda.ru
Can Sana Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Report & AI Based Trade Execution Alerts - ulpravda.ru
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.4% Following Analyst Upgrade - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $7.00 at Bank of America - MarketBeat
Buybacks Report: Can Sana Biotechnology Inc stock maintain operating marginsJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - moha.gov.vn
Big Picture: Can Sana Biotechnology Inc stock sustain market leadership - moha.gov.vn
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Promising 110.6% Potential Upside - DirectorsTalk Interviews
Institutional Investors May Overlook Sana Biotechnology, Inc.'s (NASDAQ:SANA) Recent US$120m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Sana Biotechnology (NASDAQ:SANA) Shares Down 3.3%Time to Sell? - MarketBeat
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement - MSN
Sana Biotechnology Showcases Successful In Vivo Gene Editing of Stem Cells in Nature Publication - Finviz
Sana Biotechnology showcases successful in vivo gene editing of stem cells in Nature publication - MSN
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Corient Private Wealth LLC Has $3.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ - MSN
How Sana Biotechnology Inc. stock performs in weak economyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
Sana Biotechnology (NASDAQ:SANA) Upgraded at Wall Street Zen - MarketBeat
How resilient is Sana Biotechnology Inc. stock in market downturns2025 Top Decliners & Low Risk Entry Point Guides - Улправда
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
| Wyrick Susan D. | See Remarks |
Mar 07 '25 |
Option Exercise |
0.00 |
3,250 |
0 |
158,231 |
| Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
| Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
| Wyrick Susan D. | See Remarks |
Mar 02 '25 |
Option Exercise |
0.00 |
1,525 |
0 |
155,471 |
1.24%
0.19%
자본화:
|
볼륨(24시간):